12 completed, 2 recruiting, 1 not yet recruiting, 1 terminated. 17 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 12, Recruiting 2, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
Follow Pertussis: new trials by email Literature Review of Pertussis trials Research Report on Pertussis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis | Phase 1 / Phase 2 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 380 | 2026-10-11 | 2026-10-23 |
| Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine low-dose Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content), high-dose Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content), Tetanus, Diphtheria and Acellular Pertussis Vaccine - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus | Phase 1 / Phase 2 | Not yet recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 660 | 2026-03-12 | 2026-02-18 |
| Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine DTacP (one-dose booster), DTacP (three-dose primary vaccination), DT (one-dose booster) - Diphtheria, Tetanus | Phase 1 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 460 | 2023-12-23 | 2024-01-03 |
| A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above) Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp), 23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）, Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT) - Diphtheria, Tetanus | Phase 1 | Completed | CanSino Biologics Inc. | 180 | 2023-12-06 | 2026-08-07 |
| A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 1 | Unknown | LG Chem | 42 | 2023-07-17 | 2023-07-19 |
| Establishing a Controlled Human Infection Model of Bordetella Pertussis Bordetella pertussis D420 - Pertussis | Phase 1 | Completed | Dalhousie University | 79 | 2022-01-28 | 2026-09-03 |
| Pertussis Acellular Vaccine Adjuvanted With TQL1055 TQL1055, Acellular pertussis vaccine - Pertussis | Phase 1 | Terminated | Adjuvance Technologies, Inc. | 72 | 2021-04-06 | 2022-11-01 |
| Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed . Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed, Diphtheria and Tetanus Combined Vaccine, Adsorbed, Diphtheria-tetanus-acellular pertussis vaccine - Diphtheria, Tetanus | Phase 1 | Completed | CanSino Biologics Inc. | 400 | 2020-04-28 | 2022-10-31 |
| A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults DTP-HepB-IPV-Hib vaccine, DTP-HepB-Hib vaccine & IPV - Diphtheria, Tetanus | Phase 1 | Completed | LG Chem | 42 | 2017-07-03 | 2019-08-29 |
| Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3 - Tetanus, Diphtheria | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1363 | 2015-10-22 | 2022-03-23 |
| Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine BPZE1, Placebo - Pertussis, Whooping Cough | Phase 1 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 54 | 2015-09-01 | 2026-02-27 |
| Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1) aP booster, TdaP booster, Licensed TdaP booster (Boostrix®) - Pertussis | Phase 1 | Completed | Novartis | 315 | 2015-04-01 | 2016-03-24 |
| Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap - Diphtheria, Tetanus | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 40 | 2013-08-01 | 2016-03-07 |
| Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents (ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis - Pertussis, Tetanus | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 43 | 2012-09-01 | 2014-02-21 |
| Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years Acellular pertussis vaccine, Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed), Licensed TdaP booster vaccine - Pertussis, Whooping Cough | Phase 1 | Completed | Novartis Vaccines | 420 | 2012-03-01 | 2016-04-04 |
| First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine BPZE1, Placebo - Pertussis | Phase 1 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 48 | 2010-08-01 | 2025-12-10 |
| Pertussis Vaccine in Healthy Pregnant Women Placebo, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed - Diphtheria, Pertussis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 80 | 2009-01-01 | 2014-07-25 |
Whooping Cough (17) · Diphtheria (12) · Tetanus (12) · Poliomyelitis (3) · Haemophilus Infections (2) · Hepatitis B (2) · Infections (2) · Respiratory Tract Infections (1) · Trismus (1)
Bacterial Infections (17) · Bacterial Infections and Mycoses (17) · Bordetella Infections (17) · Gram-Negative Bacterial Infections (17) · Respiratory Tract Diseases (17) · Respiratory Tract Infections (16) · Infections (15) · Actinomycetales Infections (12) · Clostridium Infections (12) · Corynebacterium Infections (12) · Gram-Positive Bacterial Infections (12) · Nervous System Diseases (4) · Central Nervous System Diseases (3) · Central Nervous System Infections (3) · Enterovirus Infections (3)
Tetanus Toxoid (8) · Diphtheria-Tetanus-acellular Pertussis Vaccines (2) · Vaccines, Combined (2) · adacel (2) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Aging (1) · Boostrix (1) · Immunization, Secondary (1) · Pentavac (1) · Poliovirus Vaccine, Inactivated (1) · Saline Solution (1)
Institute of Medical Biology, Chinese Academy of Medical Sciences (3) · Sanofi Pasteur, a Sanofi Company (3) · CanSino Biologics Inc. (2) · Institut National de la Santé Et de la Recherche Médicale, France (2) · LG Chem (2) · Adjuvance Technologies, Inc. (1) · Dalhousie University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis (1) · Novartis Vaccines (1)
China (6) · Belgium (2) · Sweden (2) · United States (2) · Australia (1) · Canada (1) · Japan (1) · South Korea (1)
Nabil Al-Tawil, MD, PhD (2) · Camille Locht, PhD (1) · Geert Leroux-Roels, Prof. Dr. (1) · Jiawei Xu (1) · Nam Joong Kim (1) · Rigmor Thorstensson, PhD (1) · Scott A. Halperin, MD (1) · Sean R Bennett, MD PhD (1) · WJ Kim (1) · Wang Yanxia (1) · Wenge Tang (1)
PMID 29172945, PMID 24261996, PMID 24421886, PMID 24793938, PMID 24794369, PMID 31945015, PMID 32687804, PMID 40977696, PMID 42369467
2014 (1), 2015 (1), R34AI148056 (1)